First-line treatment with disitamab vedotin and toripalimab improved outcomes over chemotherapy in patients with HER2-expressing, locally advanced or metastatic urothelial carcinoma.

The Inflation Reduction Act has decreased Medicare Part D expenditures and the total cost of care under the Enhancing Oncology Model but has not reduced total drug spending, data suggest.

Therapeutic plasma exchange may allow patients with advanced melanoma to overcome immune checkpoint inhibitor resistance, data suggest.

Long preoperative chemo elicited more pathologic complete responses than short preoperative chemo in PDAC, but no difference in EFS was seen.

Adjuvant cemiplimab may reduce the risk of second primary tumors in patients with high-risk cutaneous squamous cell carcinoma, data suggest.

The incidence rates for invasive lobular carcinoma increased from 2012 to 2021 for all racial and ethnic groups, according to a study published in Cancer.

Dato-DXd improved outcomes over chemotherapy in patients with locally recurrent inoperable or metastatic TNBC who were ineligible for immunotherapy.

In patients with unresectable HCC, outcomes with atezolizumab plus bevacizumab are not improved by the addition of low-dose ipilimumab.

The combination of pembrolizumab and EVX-01, a personalized peptide-based neoantigen cancer vaccine, demonstrated activity in patients with advanced melanoma, according to phase 2 study results.

Adding nimotuzumab to post-surgery adjuvant cisplatin-based chemoradiotherapy does not improve survival outcomes in patients with HNSCC.

Adding EV and pembrolizumab to surgical treatment can improve outcomes in MIBC patients who are ineligible for cisplatin, data suggest.

Data from a phase 1/2 study support the use of sevabertinib in patients with HER2-mutated NSCLC, an investigator says.